Prostate Cancer Radioligand Therapy: PSMA and Beyond, Current Landscape and Future Directions.

Area of Science:

• Oncology
• Nuclear Medicine
• Radiopharmaceutical Therapy

Background:

• Radioligand therapies are increasingly utilized for prostate cancer treatment.
• Prostate-specific membrane antigen (PSMA)-directed therapies represent a significant advancement.

Purpose of the Study:

• To review the current landscape of radioligand therapies for prostate cancer.
• To identify challenges and propose strategies for optimizing radioligand efficacy.

Main Methods:

• Literature review of published and ongoing clinical trials.
• Synthesis of current evidence on radioligand targets, radioisotopes, and combination approaches.

Main Results:

• 177Lu-PSMA-617 demonstrates improved survival in metastatic castrate-resistant prostate cancer (mCRPC) post-chemotherapy, establishing it as a standard of care.
• Ongoing trials explore novel targets, radioisotopes, and combination therapies to expand radioligand applications.

Conclusions:

• Emerging radioligands and combination strategies hold promise for improved patient outcomes.
• Optimized patient selection and dose personalization are key to enhancing radioligand therapy efficacy in prostate cancer.